- Home
- KNOP vs DRTS Comparison
KNOP vs DRTS Comparison
Compare KNOP & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | DRTS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.6M | 300.2M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNOP | DRTS |
|---|---|---|
| Price | $10.61 | $5.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 120.8K | ★ 195.5K |
| Earning Date | 12-04-2025 | 11-20-2025 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $352,712,000.00 | N/A |
| Revenue This Year | $14.84 | N/A |
| Revenue Next Year | $1.98 | N/A |
| P/E Ratio | $9.06 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $5.28 | $2.30 |
| 52 Week High | $10.99 | $5.21 |
Technical Indicators
Market Signals| Indicator | KNOP | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 59.00 | 65.63 |
| Support Level | $10.37 | $4.72 |
| Resistance Level | $10.60 | $5.20 |
| Average True Range (ATR) | 0.25 | 0.33 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 64.14 | 91.12 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.